Dupilumab Produces Early and Sustained Improvements in CSU Activity

Dupilumab produced early and sustained reductions in urticaria activity in patients with chronic spontaneous urticaria (CSU), according to “Dupilumab Provides Early and Sustained Improvement in Urticaria Activity in Patients With Chronic Spontaneous Urticaria,” a poster by Jonathan A. Bernstein, MD, et al presented as part of the “Best of the Best at Maui Derm” late breakers session at at Maui Derm Hawaii 2026.

In pooled analyses from the CUPID A and C Phase 3 trials, dupilumab significantly improved UAS7 scores beginning at Week 3, with benefits sustained through Week 24 compared with placebo. The effect was observed in antihistamine-refractory, omalizumab-naïve patients.

“Dupilumab demonstrated early and sustained improvement in urticaria activity, with a safety profile consistent with prior experience,” the authors stated.

Safety outcomes were generally consistent with the known dupilumab profile, supporting its potential role as an additional biologic option in CSU management.

“What’s important here is how quickly patients improve,” said Jason E. Hawkes, MD. “About half of the overall improvement in urticaria activity happens within the first three to four weeks, which is faster than many people might expect.”

Linda Stein Gold, MD, added, “We also don’t see conjunctivitis in urticaria the way we do in atopic dermatitis, and the safety profile was remarkably clean. This really allows dermatologists to take back management of chronic spontaneous urticaria.”